HCA250117C390000
- 0.05
- 0.000.00%
HCA Healthcare Newsroom
Optimistic Outlook and Buy Rating for HCA Healthcare Driven by Strategic Initiatives and Market Dynamics
HCA Healthcare Is Maintained at Equal-Weight by Morgan Stanley
Goldman Sachs Maintains HCA Healthcare(HCA.US) With Hold Rating, Cuts Target Price to $319
Morgan Stanley Maintains HCA Healthcare(HCA.US) With Hold Rating, Cuts Target Price to $355
HCA Healthcare Price Target Announced at $380.00/Share by JP Morgan
HCA Healthcare Analyst Ratings
Goldman Sachs Adjusts Price Target on HCA Healthcare to $319 From $359, Maintains Neutral Rating
J.P. Morgan Maintains HCA Healthcare(HCA.US) With Hold Rating, Raises Target Price to $380
Wells Fargo Downgrades HCA Healthcare(HCA.US) to Sell Rating, Cuts Target Price to $320
Wells Fargo Downgrades HCA Healthcare to Underweight From Equalweight, Adjusts Price Target to $320 From $400
HCA Healthcare Analyst Ratings
Raymond James Downgrades HCA Healthcare(HCA.US) to Hold Rating
BofA Securities Maintains HCA Healthcare(HCA.US) With Buy Rating
Barclays Maintains HCA Healthcare(HCA.US) With Buy Rating, Cuts Target Price to $392
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Moderna (MRNA) and HCA Healthcare (HCA)
HCA Healthcare Is Maintained at Equal-Weight by Wells Fargo
HCA Healthcare Analyst Ratings
Wells Fargo Maintains HCA Healthcare(HCA.US) With Hold Rating, Raises Target Price to $400
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Exact Sciences (EXAS) and Crispr Therapeutics AG (CRSP)
Cantor Fitzgerald Maintains HCA Healthcare(HCA.US) With Buy Rating, Raises Target Price to $405